Development Trend of Nanomedicines

被引：1

作者：

Kato, Kumiko ^{[1
]}

机构：

[1] Natl Inst Hlth Sci, Div Drugs, Setagaya Ku, Tokyo 1588501, Japan

来源：

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 2013年 / 133卷 / 01期

关键词：

nanomedicine; definition; liposome; iron nanoparticle; comparability; DRUG;

D O I：

10.1248/yakushi.12-00245-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nanotechnology has had a great impact on science, technology, and society since 2000, and its applications in medicine are also progressing in the diagnosis, treatment, and prevention of disease. In this review, international trends in nanomedicine regulation are introduced, including the definition of nanomedicines and the evaluation of liposomes and iron nanoparticles.

引用

页码：43 / 51

页数：9

共 16 条

[1]

[Anonymous], 2005, GUID SIM BIOL MED PR

[2]

[Anonymous], NAN REP US FDA NAN T

[3] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].

Barenholz, Yechezkel .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134

[4]

*EUR MED AG, 2006, REFL PAP NAN BAS MED

[5]

European Medicines Agency, 2011, REFL PAP DAT REQ INT

[6]

European Medicines Agency, 2010, REFL PAP NONC STUD G

[7]

Health Canada, 2010, DRUG SUBM APPL FORM

[8]

Kawanishi T, 2010, JAPANESE J GENERIC M, V4, P5

[9]

Ministry of Health Labour and Welfare, 2006, GUID BIOEQ STUD GEN

[10]

Ministry of Health Labour and Welfare, 2005, ICH HARM TRIP GUID C

← 1 2 →